Fibromyalgia Genetic Study Identifies 26 Regions Linked to Nervous System

For decades, patients suffering from widespread pain, severe fatigue, and cognitive difficulties have faced skepticism from medical practitioners who often dismissed their symptoms as psychological. Now, a massive international genetic investigation involving data from more than two million individuals provides definitive evidence that the chronic pain condition stems from a clear biological basis.

Genomic Analysis Across 2.5 Million Adults Identifies 26 Regions

The study received ethical approvals from multiple institutional review boards globally, drawing on comprehensive health datasets including the UK Biobank, the All of Us Research Program, FinnGen, the Estonian Biobank, Genes & Health, and deCODE Genetics in Iceland, alongside cohorts from Denmark and the United States. Researchers examined autosomal and chromosome X data from participants across eleven health research studies spanning seven countries, incorporating information from 55,000 diagnosed fibromyalgia patients.

By comparing the genetic differences of participants with and without the condition, the consortium pinpointed DNA sequence variants in 26 distinct regions of the human genome that influence the risk of developing fibromyalgia. Many of the genes identified within these genomic regions play direct roles in regulating brain and nerve function.

“This work changes how we think about fibromyalgia at a fundamental level. For decades, patients have been dismissed or told their pain is simply psychological. Our findings confirm the condition has a clear biological basis.”

Dr. Michael Wainberg, investigator at the Lunenfeld-Tanenbaum Research Institute, part of Sinai Health, and the University of Toronto

Co-senior authors leading the global effort included Dr. Wainberg alongside Dr. Nasa Sinnott-Armstrong at the Fred Hutch Cancer Center and the University of Washington in Seattle, and Dr. Hanna Ollila at the University of Helsinki and Massachusetts General Hospital. In the United Kingdom, researchers at King’s College London also contributed to the analysis, noting that the sheer scale of the participant pool reinforces the validity of the findings.

“By studying the DNA of over two million individuals, we can be confident that the findings are real and they suggest that fibromyalgia represents a problem in pain processing.”

Dr. Frances Williams, co-senior author and professor of genomic epidemiology at King’s College London

Unexpected Genetic Links to Huntington’s Disease Pathways

Among the 26 genetic variants discovered, the single variant showing the strongest association with fibromyalgia risk lies within the gene HTT. Mutations in this exact gene are known to cause Huntington’s disease, an inherited, progressive, and fatal neurodegenerative disorder.

A second variant pointed directly toward a cellular receptor named GPR52, which regulates HTT protein levels. Because GPR52 is already under active pharmaceutical investigation as a potential drug target for Huntington’s disease, the discovery opens a strategic pathway for repositioning existing clinical trials.

By cross-referencing their genetic discoveries with a vast repository containing 20 million cells from various tissues, the research team observed that genes positioned near fibromyalgia risk factors display heightened activity specifically in nervous system cells. This cellular enrichment pattern firmly separates fibromyalgia from classical autoimmune disorders.

Symptom Overlap and the Search for Environmental Triggers

Patients with fibromyalgia experience a wide array of physical and cognitive challenges.

• Widespread muscle pain, tenderness, and stiffness
• Persistent fatigue and sleep disturbances, including difficulty falling or staying asleep
• Cognitive difficulties often described as “fibro-fog,” affecting memory and concentration
• Frequent headaches and digestive complications such as irritable bowel syndrome
• Feelings of low mood, worry, and frustration

The investigation also uncovered substantial genetic overlap connecting fibromyalgia to other chronic conditions, including low back pain, irritable bowel syndrome, and post-traumatic stress disorder.

Despite the identification of 26 risk regions, the data shows that genetics alone does not dictate whether an individual develops the syndrome. The authors suggest that people carrying multiple risk variants likely require an additional environmental trigger—such as a painful arthritic condition—to set off the full syndrome.

While fibromyalgia is diagnosed roughly three times more frequently in women than in men, the study found no underlying genetic differences in risk between the sexes, indicating that the disparity stems from non-genetic variables like hormonal influences, environmental exposures, or diagnostic patterns.

Next Steps for the Chronic Pain Genomics Consortium

The discoveries do not yield an immediate genetic diagnostic test or a turnkey pharmaceutical cure. However, the insights provide a foundational map for future research into neural tissue changes and targeted therapies.

To continue mapping chronic pain disorders, the study’s organizers have established the Chronic Pain Genomics Consortium, which intends to investigate other poorly understood pain syndromes, beginning with pelvic pain.